Highest-materiality recent filing
GoodRx Q1 revenue $194M, raises FY2026 guidance; Pharma Direct up 82% YoY
Revenue $194.0M; net income $1.2M; adjusted EBITDA $58.3M (30.0% margin).
GoodRx appoints Thomas Chan as Chief Accounting Officer effective April 23, 2026
Thomas Chan, previously VP Corporate Controller, named Chief Accounting Officer and principal accounting officer.
Director Ian T. Clark resigns from GoodRx board; Wendy Barnes moves to Class III
Ian T. Clark resigned from the Board and Nominating & Governance Committee effective March 31, 2026.
GoodRx CAO Romin Nabiey resigns effective April 3, 2026; transition through June 8
Romin Nabiey resigned as Chief Accounting Officer, effective April 3, 2026, to pursue other opportunities.
GoodRx replaces PwC with KPMG as independent auditor for FY2026
Audit committee appointed KPMG as independent auditor for FY2026, replacing PwC.
GoodRx Holdings Approves $72,918 Cash Bonus for Chief Accounting Officer Romin Nabiey
Board approved a discretionary cash bonus of $72,918 for Romin Nabiey, Chief Accounting Officer, for 2025 performance.
GoodRx director Dipanjan Deb resigns from board effective Feb 26, 2026
Dipanjan Deb resigned as a member of GoodRx's Board of Directors effective February 26, 2026.
GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025
Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).
GoodRx grants $3M retention bonuses to CEO and CFO
CEO Wendy Barnes receives $2M retention bonus; CFO Chris McGinnis receives $1M.
GoodRx Q3 revenue $196M, net income $1.1M; raises manufacturer solutions outlook to ~35% growth
Revenue of $196.0M; net income $1.1M (0.6% margin).
GoodRx Co-Chairman Trevor Bezdek ends executive employment, remains as non-employee director
Employment terminated by mutual agreement on Nov 1, 2025; Bezdek stays as Co-Chairman of the Board.
GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY
Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).
GoodRx stockholders elect three Class II directors and ratify auditor at 2025 annual meeting
Elected Christopher Adams, Trevor Bezdek, and Scott Wagner as Class II directors; each received >2.6B votes for.
GoodRx Q1 2025 revenue in-line at $203M; raises FY adjusted EBITDA guidance
Revenue $203.0M, net income $11.1M (net income margin 5.4%).
GoodRx to repurchase 20M shares from three major holders at $4.20/share (5% discount)
Repurchases 3M shares from Spectrum, 10M from Francisco Partners, and 7M from Idea Men; total 20M shares.
GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M
Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).
GoodRx names Christopher McGinnis as CFO, effective Feb 4, 2025
McGinnis was CEO of Citizens Rx; succeeds Romin Nabiey (interim CFO), who remains CAO.
GoodRx appoints Scott Wagner as director, co-chair; Simon Patterson resigns from board
Scott Wagner appointed Class II director, Chair of Compensation Committee, and Co-Chair of the Board effective Jan 21, 2025.
GoodRx CFO Karsten Voermann resigns; CAO Romin Nabiey named interim CFO
Karsten Voermann resigns as CFO effective Jan 17, 2025, for personal reasons, not due to any disagreement.
GoodRx appoints Wendy Barnes as CEO and President, effective Jan 1, 2025
Wendy Barnes named CEO/President, succeeding interim CEO Scott Wagner; also elected Class I director.
GoodRx Q3 2024 revenue $195.3M, net income $4.0M, Adjusted EBITDA $65.0M
Revenue and Adjusted Revenue both $195.3 million for Q3 2024.
GoodRx adds IQVIA CFO Bruehlman to board; Bezdek extends contract with no severance
Ronald E. Bruehlman (IQVIA CFO) elected to Board and as Audit & Risk Committee chair, effective Nov 8, 2024.
GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M
Revenue and Adjusted Revenue of $200.6M for Q2 2024.
GoodRx enters Sixth Amendment to Credit Agreement, refinances $500M term loan facility
New $500M 2024 Term Loan Facility matures July 2029 with SOFR + 3.75% margin, used to repay Existing Term Loans ($167.2M cash added).
GoodRx adds former Genentech CEO Ian Clark to board, creates Innovation Committee
Ian T. Clark elected Class III director effective July 8, 2024; fills vacancy from Stephen LeSieur's March resignation.
GoodRx stockholders elect three Class I directors, ratify auditor, approve say-on-pay
Elected Douglas Hirsch, Kelly J. Kennedy, and Agnes Rey-Giraud as Class I directors for terms through 2027.
GoodRx elects Simon Patterson to fill board vacancy
Simon Patterson elected as Class II director effective May 29, 2024, term expires at 2025 annual meeting.
GoodRx Q1 2024 revenue $197.9M; adjusted EBITDA $62.8M
Revenue (GAAP and adjusted) of $197.9M; net loss $1.0M; adjusted net income $32.6M.
GoodRx interim CEO Scott Wagner extends commitment; two board directors resign
Scott Wagner's employment agreement revised to indefinite term, annual cash bonus target 100% of base salary.
GoodRx repurchases 20.9M shares from Spectrum, Francisco Partners at $7.19, discount to $7.57 close
Repurchases 6,239,942 shares from Spectrum and 14,622,366 from Francisco Partners, total 20,862,308 shares.
GoodRx CFO Karsten Voermann enters new employment agreement, receives $5M equity and special bonus
New agreement sets base salary at $450,000, target bonus of 100% of salary, and $5M equity award (50% option, 50% RSU) vesting over 4 years.
GoodRx Q4 revenue $196.6M; net loss $25.9M; adj. EBITDA $57.3M
Q4 2023 revenue $196.6M, net loss $25.9M (13.2% margin), adjusted net income $31.1M (15.8% margin).
GoodRx extends $100M revolver to July 2025, COO Raj Beri departs with severance
Revolver maturity extended from Oct 11, 2024 to July 11, 2025; other terms unchanged.
On February 4, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer of the Company, effective as of his commencement of employment, which occurred on February 4, 2025 (the “Effective Date”).
Mr. McGinnis succeeds Romin Nabiey who, as previously disclosed, has been serving as Interim Chief Financial Officer.
On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.
On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee.
The Board also appointed Mr. Wagner as the Chair of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.
On January 10, 2025, the Board of Directors (the “Board”) of the Company appointed Romin Nabiey, the Company’s current Chief Accounting Officer, as Interim Chief Financial Officer of the Company, effective as of the Effective Date.
On January 7, 2025, Karsten Voermann submitted his resignation as Chief Financial Officer of GoodRx Holdings, Inc. (the “Company”), effective January 17, 2025 (the “Effective Date”) for personal reasons.
On October 25, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ronald E. Bruehlman as a Class III director, effective as of the Effective Date, to fill the vacancy on the Board created by the resignation of Julie Bradley.
On October 22, 2024, Julie Bradley notified GoodRx Holdings, Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), including from her service on the Board’s Audit and Risk Committee, effective as of November 8, 2024 (the “Effective Date”).
On July 8, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Ian T. Clark as a Class III director, effective immediately, to fill the vacancy on the Board created by the resignation of Stephen LeSieur.
On May 29, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance Committee, elected Simon Patterson as a Class II director, effective immediately, to fill the vacancy on the Board created by the resignation of Adam Karol.
On March 12, 2024, Adam Karol notified the Company of his decision to resign as a member of the Board, effective as of March 22, 2024, including from his service on the Board’s Compliance Committee and Nominating and Corporate Governance Committee.
Max materiality 0.90 · Median 0.60 · Most common event leadership